logo

Humanigen, Inc (HGEN)



Trade HGEN now with
  Date
  Headline
8/12/2022 4:12:46 PM Humanigen Q2 Loss/share $0.43 Vs. Loss $1.20 Year Ago
6/16/2022 6:35:26 AM Humanigen Enters Deal With PCI Pharma Services For Commercialization In The United Kingdom
2/10/2022 12:00:29 AM Humanigen Says Lenzilumab Is Now Available For COVID-19 Patients Through Newly-launched Managed Access Program
2/8/2022 11:59:49 PM Humanigen, Cenexi Announce Collaboration To Manufacture Lenzilumab In France
1/10/2022 6:09:02 AM Humanigen Outlines Next Steps For Development Of Lenzilumab In The Prevention Of CAR-T Therapy Related Toxicities
1/5/2022 6:08:33 AM Humanigen Achieves Target Enrollment In Phase 2/3 ACTIV-5/BET-B Trial Of Lenzilumab For COVID-19
11/11/2021 6:35:38 AM Humanigen Reports Clinical Trial Collaboration To Evaluate Lenzilumab In Acute Graft Versus Host Disease
10/26/2021 6:37:02 AM Humanigen : First Patient Dosed In Phase 2 Medicine Study Of Lenzilumab In Patients With Chronic Myelomonocytic Leukemia
6/14/2021 6:34:29 AM Humanigen Begins Rolling Review Submission For Marketing Authorization By MHRA For Lenzilumab
4/19/2021 7:11:13 AM Humanigen Reports Positive Data With Lenzilumab In ZUMA-19 CAR-T Phase 1b Study In DLBCL
4/9/2021 7:03:01 AM Humanigen Announces Positive Results From Phase 1 Study Of Ifabotuzumab In Glioblastoma Multiforme
3/29/2021 7:07:49 AM Humanigen Announces Positive Topline Results From Phase 3 Clinical Trial Evaluating Lenzilumab